Survanta Intratracheal suspension
Phospholipids
25mg/ml
Marketed By Unimed & Unihealth Manufacturers Ltd (Abbott Pharma Product)
| Pack size | 4ml vial, 8ml vial |
|---|---|
| Unite Price | 27500, 33000 BDT |
Indications
Survanta Intratracheal suspension is used for:
Resp distress syndrome (RDS) in premature infants.
Adult Dose
Child Dose
Prevention in premature infant <1250 g birthwt or w/ evidence of surfactant deficiency
Preferably w/in 15 mins of birth.
Rescue Preferably by 8 hr of age.
4 mL/kg birth wt(100 mg of phospholipids/kg birth wt) intratracheally up to 4 doses in 1st 48 hr.
Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.
Renal Dose
Administration
Contra Indications
None known.
Precautions
Infants <600 g birth wt. For intratracheal use only.
Pregnancy-Lactation
Interactions
Side Effects
Side effects of Phospholipids :
Transient bradycardia. O2 desaturation, endotracheal tube reflux & blockage, pallor, vasoconstriction, hypotension, HTN, hypocarbia, hypercarbia & apnea.
Mode of Action
Natural bovine pulmonary surfactant; replaces deficient endogenous lung surfactant in neonates with respiratory distress syndrome.
Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between alveolar surfaces and air.
Note
Survanta 25mg/ml Intratracheal suspension generic name is Phospholipids. Survanta 25mg/ml Intratracheal suspension is manufactured by Marketed By Unimed & Unihealth Manufacturers Ltd (Abbott Pharma Product)Survanta is availble in all over Bangladesh.
Mes BD drug index information on Survanta Intratracheal suspension is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.